Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine
Immunogenicity and safety of a hexavalent meningococcal outermembrane-vesicle vaccine in children of 2-3 and 7-8 years of age
Carriage of meningococci in contacts of patients with meningococcal disease. Age and other risk factors need to be taken into account [Letter to the editor]
Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease
Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? Experience from the Netherlands
Acute incidenten, opgetreden tijdens de massavaccinatie van de MenC campagne in 2002, gericht tegen Meningokokken groep C